- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03600818
Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica
Primary Objective:
To evaluate the efficacy of KEVZARA (sarilumab) in participants with polymyalgia rheumatica (PMR) as assessed by the proportion of participants with sustained remission for sarilumab with a shorter corticosteroid (CS) tapering regimen as compared to placebo with a longer CS tapering regimen.
Secondary Objectives:
- To demonstrate the efficacy of sarilumab in participants with PMR compared to placebo, in combination with a CS taper with regards to:
- Clinical responses (such as components of sustained remission, disease remission rates, time to first disease flare) over time.
- Cumulative CS (including prednisone) exposure.
- To assess the safety (including immunogenicity) and tolerability of sarilumab in participants with PMR.
- To measure sarilumab serum concentrations in participants with PMR.
- To assess the effect of sarilumab in reducing glucocorticoid toxicity as measured by the composite glucocorticoid toxicity index (GTI) questionnaire.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Buenos Aires, Argentina, C1015ABO
- Investigational Site Number 0320001
-
Buenos Aires, Argentina, C1121ABE
- Investigational Site Number 0320005
-
Caba, Argentina, C1181ACH
- Investigational Site Number 0320002
-
San Miguel de Tucuman, Argentina, T4000AXL
- Investigational Site Number 0320003
-
-
-
-
-
Camberwell, Australia, 3124
- Investigational Site Number 0360003
-
Kogarah, Australia, 2217
- Investigational Site Number 0360001
-
Maroochydore, Australia, 4558
- Investigational Site Number 0360002
-
Woodville South, Australia, 5011
- Investigational Site Number 0360004
-
-
-
-
-
Gent, Belgium, 9000
- Investigational Site Number 0560003
-
Leuven, Belgium, 3000
- Investigational Site Number 0560001
-
-
-
-
-
Hamilton, Canada, L8N 1Y2
- Investigational Site Number 1240007
-
Montreal, Canada, H4A 3T2
- Investigational Site Number 1240010
-
Rimouski, Canada, G5L 5T1
- Investigational Site Number 1240001
-
Sherbrooke, Canada, J1G 2E8
- Investigational Site Number 1240005
-
Trois-Rivières, Canada, G8Z 1Y2
- Investigational Site Number 1240003
-
-
-
-
-
Tallinn, Estonia, 13419
- Investigational Site Number 2330001
-
-
-
-
-
Brest Cedex, France, 29609
- Investigational Site Number 2500005
-
Caen Cedex 9, France, 14033
- Investigational Site Number 2500011
-
Le Kremlin Bicetre, France, 94270
- Investigational Site Number 2500015
-
Lille Cedex, France, 59037
- Investigational Site Number 2500010
-
Montivilliers, France, 76290
- Investigational Site Number 2500002
-
Montpellier, France, 34295
- Investigational Site Number 2500003
-
Paris, France, 75013
- Investigational Site Number 2500004
-
Pierre Benite Cedex, France, 69495
- Investigational Site Number 2500016
-
Toulouse Cedex 09, France, 31059
- Investigational Site Number 2500014
-
-
-
-
-
Bad Abbach, Germany, 93077
- Investigational Site Number 2760008
-
Berlin, Germany, 13125
- Investigational Site Number 2760001
-
Berlin, Germany, 10117
- Investigational Site Number 2760009
-
Dresden, Germany, 01307
- Investigational Site Number 2760002
-
Kirchheim Unter Teck, Germany, 73230
- Investigational Site Number 2760003
-
München, Germany, 80336
- Investigational Site Number 2760004
-
Tübingen, Germany, 72076
- Investigational Site Number 2760007
-
-
-
-
-
Debrecen, Hungary, 4032
- Investigational Site Number 3480001
-
-
-
-
-
Haifa, Israel, 34362
- Investigational Site Number 3760004
-
Haifa, Israel, 31096
- Investigational Site Number 3760001
-
Kfar Saba, Israel, 44281
- Investigational Site Number 3760003
-
Petah-Tikva, Israel, 49100
- Investigational Site Number 3760002
-
Tel Hashomer, Israel, 52621
- Investigational Site Number 3760005
-
-
-
-
-
Milano, Italy, 20132
- Investigational Site Number 3800001
-
Milano, Italy, 20122
- Investigational Site Number 3800003
-
Pisa, Italy, 56126
- Investigational site number 3800004
-
Reggio Emilia, Italy, 42100
- Investigational Site Number 3800002
-
Rozzano, Italy, 20089
- Investigational Site Number 3800005
-
Verona, Italy, 37134
- Investigational Site Number 3800008
-
-
-
-
-
Fuchu-Shi, Japan
- Investigational Site Number 3920002
-
Kamakura-Shi, Japan
- Investigational Site Number 3920003
-
Kawachinagano-Shi, Japan
- Investigational Site Number 3920005
-
Takasaki-Shi, Japan
- Investigational Site Number 3920001
-
-
-
-
-
Alkmaar, Netherlands, 1815 JD
- Investigational Site Number 5280003
-
Almelo, Netherlands, 7609 PP
- Investigational Site Number 5280002
-
Den Haag, Netherlands, 2545 CH
- Investigational Site Number 5280007
-
Leeuwarden, Netherlands, 8934 AD
- Investigational Site Number 5280005
-
Nijmegen, Netherlands, 6522 JV
- Investigational Site Number 5280004
-
Rotterdam, Netherlands, 3079
- Investigational Site Number 5280008
-
-
-
-
-
Moscow, Russian Federation, 115404
- Investigational Site Number 6430002
-
Moscow, Russian Federation, 123182
- Investigational Site Number 6430003
-
Moscow, Russian Federation, 121374
- Investigational Site Number 6430001
-
Moscow, Russian Federation, 129110
- Investigational Site Number 6430004
-
Saint-Petersburg, Russian Federation, 192242
- Investigational Site Number 6430008
-
-
-
-
-
A Coruña / Santiago De Compostela, Spain, 15706
- Investigational Site Number 7240004
-
Badalona, Spain, 08916
- Investigational Site Number 7240005
-
Getafe, Spain, 28905
- Investigational Site Number 7240001
-
Granada, Spain, 18014
- Investigational Site Number 7240008
-
Madrid, Spain, 28041
- Investigational Site Number 7240002
-
Santander, Spain, 39008
- Investigational Site Number 7240006
-
Valencia, Spain, 46026
- Investigational Site Number 7240007
-
-
-
-
-
Bern, Switzerland, 3010
- Investigational Site Number 7560001
-
St. Gallen, Switzerland, 9007
- Investigational Site Number 7560002
-
-
-
-
-
Gateshead, United Kingdom, NE9 6SX
- Investigational Site Number 8260004
-
Leeds, United Kingdom, LS7 4SA
- Investigational Site Number 8260003
-
Manchester, United Kingdom, M23 9LT
- Investigational Site Number 8260009
-
Newport, United Kingdom, PO30 5TG
- Investigational Site Number 8260007
-
Plymouth, United Kingdom, PL6 8DH
- Investigational Site Number 8260002
-
Southend, United Kingdom, SS0 0RY
- Investigational Site Number 8260001
-
-
-
-
California
-
Upland, California, United States, 91786
- Investigational Site Number 8400003
-
-
Colorado
-
Denver, Colorado, United States, 80230
- Investigational Site Number 8400005
-
-
Connecticut
-
Stamford, Connecticut, United States, 06905
- Investigational Site Number 8400009
-
-
Florida
-
Boca Raton, Florida, United States, 33486
- Investigational Site Number 8400002
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Investigational Site Number 8400014
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Investigational Site Number 8400006
-
-
New York
-
New York, New York, United States, 11201
- Investigational Site Number 8400022
-
-
Texas
-
Dallas, Texas, United States, 75231
- Investigational Site Number 8400011
-
Lufkin, Texas, United States, 75904
- Investigational Site Number 8400025
-
-
Washington
-
Spokane, Washington, United States, 99024
- Investigational Site Number 8400015
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria :
- Diagnosis of PMR according to European League Against Rheumatism/American College of Rheumatology classification criteria.
- Participants must be on prednisone of at least 7.5 milligrams per day (mg/day) (or equivalent) and not exceeding 20 mg/day at screening and during the screening period.
- Participant was willing and able to take prednisone of 15 mg/day at randomization.
- Participants had a history of being treated for at least 8 weeks with prednisone (greater than or equal to [>=]10 mg/day or equivalent).
Participants must have had at least one episode of unequivocal PMR flare while attempting to taper prednisone at a dose that was >= 7.5 mg/day (or equivalent) within the past 12 Weeks prior to screening:
- Unequivocal symptoms of PMR flare included shoulder and/or hip girdle pain associated with inflammatory stiffness.
- Participants had erythrocyte sedimentation rate >=30 millimeters per hour (mm/hr) and/or C-reactive protein >=10 milligrams per liter (mg/L) associated with PMR disease activity within 12 weeks prior to screening.
Exclusion criteria:
- Diagnosis of giant cell arteritis (e.g., persistent or recurrent localized headache, temporal artery or scalp tenderness, jaw claudication, extremity claudication, blurry or loss of vision, symptoms of stroke).
- Diagnosis of active fibromyalgia.
- Concurrent rheumatoid arthritis or other inflammatory arthritis or other connective tissue diseases, such as but not limited to systemic lupus erythematosus, systemic sclerosis, vasculitis, myositis, mixed connective tissue disease, and ankylosing spondylitis.
- Concurrent diagnosis of rhabdomyolysis or neuropathic muscular diseases.
- Inadequately treated hypothyroidism.
- Organ transplant recipient.
- Therapeutic failure including inadequate response or intolerance, or contraindication, to biological interleukin-6 antagonist.
Any prior (within the defined period below) or concurrent use of immunosuppressive therapies but not limited to any of the following:
- Janus kinase inhibitor within 4 weeks of Baseline.
- Alkylating agents including cyclophosphamide within 6 months of Baseline.
- Cell-depletion agents (e.g., anti CD20) without evidence of recovery of B cells to Baseline level.
- Tumor necrosis factor inhibitors within 2-8 weeks (etanercept within 2 weeks, infliximab, certolizumab, golimumab, or adalimumab within 8 weeks), or after at least 5 half-lives have elapsed, whichever was longer.
- Abatacept within 8 weeks of Baseline.
- Anakinra within 1 week of Baseline.
- Cyclosporine, azathioprine or mycophenolate mofetil or leflunomide within 4 weeks of Baseline.
- Unstable methotrexate (MTX) dose and/or MTX dose greater than (>) 15 mg/week within 3 months of Baseline
- Concurrent use of systemic CS for conditions other than PMR.
- Pregnant or breastfeeding woman.
- Participants with active or untreated latent tuberculosis.
- Participants with history of invasive opportunistic infections.
- Participants with fever associated with infection or chronic, persistent or recurring infections required active treatment.
- Participants with uncontrolled diabetes mellitus.
- Participants with non-healed or healing skin ulcers.
- Participants who received any live, attenuated vaccine within 3 months of Baseline.
- Participants who were positive for hepatitis B, hepatitis C and/or human immunodeficiency virus.
- Participants with a history of active or recurrent herpes zoster.
- Participants with a history of or prior articular or prosthetic joint infection.
- Prior or current history of malignancy.
- Participants who have had surgery within 4 weeks of screening or planned surgery during study.
- Participants with a history of inflammatory bowel disease or severe diverticulitis or previous gastrointestinal perforation.
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo+52 Week Taper
Participants received sarilumab-matching placebo as subcutaneous (SC) injection every 2 weeks (q2w) up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule.
Participants received prednisone/prednisone-matching placebo tapering oral daily doses for 52 weeks.
|
Pharmaceutical form:solution for injection Route of administration: subcutaneous
Pharmaceutical form:over-encapsulated tablets Route of administration: oral administration
Pharmaceutical form:over-encapsulated tablets Route of administration: oral administration
Pharmaceutical form:tablets Route of administration: oral administration
|
Experimental: Sarilumab 200mg q2w+14 Week Taper
Participants received sarilumab 200 milligrams (mg) as SC injection q2w up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule.
Participants received prednisone tapering oral daily doses during the first 14 weeks and prednisone-matching placebo from Week 14 up to Week 52.
|
Pharmaceutical form:over-encapsulated tablets Route of administration: oral administration
Pharmaceutical form:over-encapsulated tablets Route of administration: oral administration
Pharmaceutical form:tablets Route of administration: oral administration
Pharmaceutical form:solution for injection Route of administration: subcutaneous
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Achieving Sustained Remission at Week 52
Time Frame: At Week 52
|
Sustained remission was defined as meeting all of the following parameters: achievement of disease remission (defined as resolution of signs and symptoms of polymyalgia rheumatica [PMR], and normalization of C-reactive protein [CRP] {less than [<]10 milligrams per liter [mg/L]}) not later than Week 12, absence of disease flare (defined as recurrence of signs and symptoms attributable to active PMR plus an increase in corticosteroid [CS] dose due to PMR or elevation of erythrocyte sedimentation rate [ESR] attributable to active PMR plus an increase in CS dose due to PMR) from Week 12 through Week 52, sustained reduction of CRP (to <10 mg/L, with absence of successive elevations to greater than or equal to [>=]10 mg/L) from Week 12 through Week 52, and successful adherence to prednisone taper from Week 12 through Week 52.
|
At Week 52
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total Cumulative Corticosteroid Dose
Time Frame: Up to Week 52
|
Cumulative dose of CS used for PMR disease was defined as the dose taken up to the end of treatment, including expected prednisone in tapering regimen per protocol, add-on prednisone, CS used in rescue therapy and the use of commercial prednisone (an excess of <=100 mg of prednisone during the study treatment period).
The total cumulative CS dose was based on the total number of days with complete or partial intake, no imputation was done on missed tablets.
|
Up to Week 52
|
Number of Participants Who Achieved Disease Remission up to Week 12
Time Frame: Up to Week 12
|
Disease remission was defined as resolution of signs and symptoms of PMR, and normalization of CRP (< 10 mg/L).
The status of normalization of CRP (<10 mg/L) was determined based on the last two non-missing post-baseline CRP values measured up to Week 12.
If at least one of the value was <10 mg/L, then it was considered as normalization of CRP.
Participants who took rescue CS due to active PMR prior to Week 12 or who permanently withdrew from the study treatment prior to Week 12 were considered as not achieved disease remission by Week 12.
During the initial 12 weeks of prednisone taper, treatment for one flare before Week 12 was permitted if it was successfully treated with a low dose (<=5 mg/day) prednisone add-on taper regimen (completed prior to Week 12) and provided that all other sustained remission parameters were met.
|
Up to Week 12
|
Number of Participants With Absence of Disease Flare From Week 12 Through Week 52
Time Frame: From Week 12 Through Week 52
|
Disease flare was defined as either recurrence of signs and symptoms attributable to active PMR plus an increase in CS dose due to PMR, or elevation of ESR attributable to active PMR plus an increase in CS dose due to PMR.
|
From Week 12 Through Week 52
|
Number of Participants With Sustained Reduction of CRP From Week 12 Through Week 52
Time Frame: From Week 12 through Week 52
|
Normalization (sustained reduction) of CRP was defined as CRP levels <10 mg/L.
If there were two or more consecutive visits with CRP >=10 mg/L, then it was categorized as no normalization of CRP.
|
From Week 12 through Week 52
|
Number of Participants With Successful Adherence to the Prednisone Taper From Week 12 Through Week 52
Time Frame: From Week 12 through Week 52
|
Successful adherence to the prednisone taper from Week 12 through Week 52 was defined as participants who did not take rescue therapy from Week 12 through Week 52 and any excess prednisone (beyond the per protocol CS tapering regimen) with a cumulative dose of <=100 mg (or equivalent), such as those employed to manage adverse event (AE) not related to PMR.
|
From Week 12 through Week 52
|
Time to First Polymyalgia Rheumatica Flare After Clinical Remission up to Week 52
Time Frame: Up to Week 52
|
Time to first PMR flare was defined as the duration (in days) from randomization to first PMR flare after clinical remission (defined as resolution of signs and symptoms and normalization of CRP [<10 mg/L]) and up to 52 weeks.
Disease flare was defined as either the recurrence of signs or symptoms attributable to active plus an increase in CS dose due to PMR or elevation of ESR attributable to active PMR plus an increase in CS dose due to PMR.
Kaplan-Meier method was used for the analysis.
Participants who never achieved remission were censored at randomization day; and those who achieved clinical remission and never flared were censored at the end of treatment assessment date up to Week 52.
|
Up to Week 52
|
Composite Glucocorticoid Toxicity Index (C-GTI): Cumulative Worsening Score (CWS) and Aggregate Improvement Score (AIS) at Week 52
Time Frame: At Week 52
|
GTI assessed glucocorticoid (GC) related morbidity and GC-sparing ability of other therapies; composed of 2 components: C-GTI and Specific List.
C-GTI contained 9 domains and Specific List contained of 23 items (11 domains), used as complementary tool to C-GTI.
C-GTI score was sum of 9 domain-specific scores at each visit and Cumulative GTI score was sum of C-GTI scores across each visit.
Two cumulative GTI scores: CWS and AIS at Week 52 are reported in this outcome measure.
CWS assessed cumulative GC toxicity regardless of whether toxicity had lasting effects or was transient.
AIS assessed new therapy effectiveness in decreasing any Baseline GC toxicity over time.
Negative scores reflect improvement in CS toxicities present from Baseline.
For CWS, composite score ranged from 0 to 439 and for AIS, composite score ranged from -346 to 439.
For both CWS and AIS, minimum score implies least toxicity and maximum score implies most toxicity.
|
At Week 52
|
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
Time Frame: From first dose (i.e. Day 1) up to 60 days after last dose date of study drug (i.e. up to Week 60)
|
An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment.
Serious AEs (SAEs) were any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event.
TEAEs were the AEs that developed or worsened or became serious during the TEAE period (defined as the time from the first dose of the investigational medicinal product (IMP) to the last dose of the IMP +60 days).
|
From first dose (i.e. Day 1) up to 60 days after last dose date of study drug (i.e. up to Week 60)
|
Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities During TEAE Period
Time Frame: From first dose (i.e., Day 1) up to 60 days after last dose date of study drug (i.e., up to Week 60)
|
Criteria for potentially clinically significant vital sign abnormalities: Systolic Blood Pressure (SBP): <= 95 mmHg and decrease from baseline (DFB) more than or equal to (>=) 20 mmHg; >= 160 mmHg and increase from baseline (IFB) >= 20 mmHg Diastolic blood pressure (DBP): <=45 mmHg and DFB >=10 mmHg; >=110 mmHg and IFB >=10 mmHg. Heart Rate (HR): <= 50 beats per min (bpm) and DFB >=20 bpm; >=120 bpm and IFB >= 20 bpm Weight: >=5% DFB; >=5% IFB. TEAE period was defined as the time from the first dose of the IMP to the last dose of the IMP + 60 days. |
From first dose (i.e., Day 1) up to 60 days after last dose date of study drug (i.e., up to Week 60)
|
Number of Participants With Potentially Clinically Significant Abnormalities - Hematological Parameter
Time Frame: From first dose (i.e., Day 1) up to 60 days after last dose date of study drug (i.e., up to Week 60)
|
Criteria for potentially clinically significant laboratory abnormalities included: Hemoglobin (Hb): <= 115 grams per liter (g/L) (Male [M]), <= 95 g/L (Female [F]); >= 185 g/L (M), >= 165 g/L (F); DFB >= 20 g/L . Hematocrit: <= 0.37 volume/volume (v/v) (M); <= 0.32 v/v (F); >= 0.55 v/v (M); >= 0.5 v/v (F). Erythrocytes: >=6 Tera/ liter (L). Platelets: < 100 Giga/L, >= 700 Giga/L. Leukocytes: < 3.0 Giga/L (Non-Black [NB]); < 2.0 Giga/L (Black [B]), >= 16.0 Giga/L. Neutrophils: < 1.5 Giga/L (NB); < 1.0 Giga/L (B). Lymphocytes: > 4.0 Giga/L. Monocytes: > 0.7 Giga/L. Basophils: > 0.1 Giga/L. Eosinophils: > 0.5 Giga/L or > upper limit of normal (ULN) (if ULN >= 0.5 Giga/L). |
From first dose (i.e., Day 1) up to 60 days after last dose date of study drug (i.e., up to Week 60)
|
Number of Participants With Potentially Clinically Significant Abnormalities - Metabolic Parameters
Time Frame: From first dose (i.e., Day 1) up to 60 days after last dose date of study drug (i.e., up to Week 60)
|
Criteria for potentially clinically significant abnormalities: Glucose: <=3.9 millimoles (mmol)/L and < lower limit of normal (LLN); >=11.1 mmol/L (unfasted [unfas]); >=7 mmol/L (fasted [fas]). HbA1c: >8%. Cholesterol: >=7.74 mmol/L. Triglycerides: >=4.6 mmol/L. C Reactive Protein (CRP): >2 ULN or >10 mg/L (if ULN not provided). |
From first dose (i.e., Day 1) up to 60 days after last dose date of study drug (i.e., up to Week 60)
|
Number of Participants With Potentially Clinically Significant Abnormalities - Renal Function
Time Frame: From first dose (i.e., Day 1) up to 60 days after last dose date of study drug (i.e., up to Week 60)
|
Criteria for potentially clinically significant abnormalities: Creatinine: >=150 micromol/L (adults); >=30% change from baseline, >=100% change from baseline. Creatinine clearance: >=60 to <90 milliliters per minute (mL/min); >=30 to <60 mL/min ; >=15 to <30 mL/min; <15 mL/min. Blood urea nitrogen: >=17 mmol/L. Urate: <120 micromol/L; >408 micromol/L. |
From first dose (i.e., Day 1) up to 60 days after last dose date of study drug (i.e., up to Week 60)
|
Number of Participants With Potentially Clinically Significant Abnormalities - Liver Function
Time Frame: From first dose (i.e., Day 1) up to 60 days after last dose date of study drug (i.e., up to Week 60)
|
Criteria for potentially clinically significant abnormalities: Albumin: <= 25 g/L. Alanine Aminotransferase (ALT): >3 ULN; >5 ULN; >10 ULN. Aspartate Aminotransferase (AST): >3 ULN; >5 ULN; >10 ULN; >20 ULN. Alkaline Phosphatase: >1.5 ULN. Bilirubin: >1.5 ULN; >2 ULN. ALT and Total Bilirubin: ALT > 3 ULN and Bilirubin > 2 ULN |
From first dose (i.e., Day 1) up to 60 days after last dose date of study drug (i.e., up to Week 60)
|
Number of Participants With Treatment-emergent Antidrug Antibodies (ADA) Response
Time Frame: From first dose (i.e., Day 1) up to 60 days after last dose date of study drug (i.e., up to Week 60)
|
ADA response categories: 1) Treatment-boosted ADA positive participant: Participant with a positive ADA assay response at Baseline and with at least a 4-fold increase in titer compared to Baseline during TEAE period.
2) Treatment-emergent ADA positive participant: Participant with non-positive assay (meaning negative or missing) response at Baseline but with a positive assay response during the TEAE period (defined as the time from the first dose of the IMP to the last dose of the IMP +60 days).
|
From first dose (i.e., Day 1) up to 60 days after last dose date of study drug (i.e., up to Week 60)
|
Pharmacokinetics (PK): Serum Trough Concentration (Ctrough) of Sarilumab
Time Frame: Pre-dose on Week 0 (Baseline), Week 2, 4, 12, 16, 24, and 52
|
Ctrough was pre dose concentration of drug.
Data for this outcome measure was not planned to be collected and analyzed for placebo arm (Placebo+52 Week Taper) as pre-specified in the protocol.
|
Pre-dose on Week 0 (Baseline), Week 2, 4, 12, 16, 24, and 52
|
Pharmacokinetics: Serum Drug Concentration of Sarilumab Post-dose at Week 24
Time Frame: Post-dose at Week 24
|
Serum concentrations of functional sarilumab were analyzed using validated enzyme linked immunosorbent assay.
|
Post-dose at Week 24
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Skin Diseases
- Immune System Diseases
- Autoimmune Diseases of the Nervous System
- Autoimmune Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Muscular Diseases
- Vasculitis
- Skin Diseases, Vascular
- Vasculitis, Central Nervous System
- Arteritis
- Polymyalgia Rheumatica
- Giant Cell Arteritis
- Physiological Effects of Drugs
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Prednisone
Other Study ID Numbers
- EFC15160
- 2017-002989-42 (EudraCT Number)
- U1111-1201-0777 (Other Identifier: UTN)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Polymyalgia Rheumatica
-
University Hospital, Basel, SwitzerlandNovartis; Schweizerische Stiftung für die Erforschung der MuskelkrankheitenRecruitingPolymyalgia Rheumatica (PMR) | Giant Cell Arteritis (GCA)Switzerland
-
Hospital for Special Surgery, New YorkGenentech, Inc.Completed
-
University Hospital, BrestEli Lilly and CompanyCompletedPolymyalgia Rheumatic (PMR)France
-
Insel Gruppe AG, University Hospital BernPaul Scherrer Institut, Center for Proton TherapyNot yet recruitingGiant Cell ArteritisSwitzerland
-
GMIOFranceNot yet recruitingGiant Cell Arteritis | Aortitis
-
Centre Hospitalier Universitaire DijonNot yet recruiting
-
Fondation Ophtalmologique Adolphe de RothschildNot yet recruiting
-
University of PennsylvaniaRecruiting
-
Centre Hospitalier William Morey - Chalon sur SaôneCentre Hospitalier de MâconRecruitingGiant Cell Arteritis | Tomography, Optical CoherenceFrance
-
Rigshospitalet, DenmarkRecruiting
Clinical Trials on Sarilumab-matching placebo
-
SanofiRegeneron PharmaceuticalsTerminatedGiant Cell ArteritisArgentina, Estonia, France, United States, Australia, Belgium, Canada, Croatia, Denmark, Germany, Hungary, Israel, Italy, Netherlands, Portugal, Russian Federation, Slovenia, Spain, Sweden, Switzerland, United Kingdom
-
National Institute of Allergy and Infectious Diseases...CompletedIndolent Systemic MastocytosisUnited States
-
Regeneron PharmaceuticalsSanofiCompletedCOVID-19United States
-
Stanford UniversityCompleted
-
GlaxoSmithKlineIqvia Pty LtdCompletedArthritis, RheumatoidUnited States, Germany, Canada, Czechia, Poland, South Africa, Korea, Republic of, Spain, Japan, Argentina, Belgium, Hungary, United Kingdom, Italy, Lithuania
-
Assistance Publique - Hôpitaux de ParisUnknown
-
SanofiRegeneron PharmaceuticalsCompletedRheumatoid ArthritisUnited States, Chile, Czechia, Germany, Hungary, Israel, Peru, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine, Korea, Republic of, United Kingdom
-
Westyn Branch-EllimanCompleted
-
SanofiRegeneron PharmaceuticalsCompletedAnkylosing SpondylitisGermany, Hungary, Belgium, Czechia, Austria, Canada, Lithuania, Poland, Spain, Turkey, France, Netherlands, United States, Australia
-
Clinica Universidad de Navarra, Universidad de...Sanofi; Hospital Universitario Infanta LeonorUnknownCOVID-19 Drug TreatmentSpain